Takeda Tadashi, Tatsumi Nobuyuki, Nakayama Yuji, Yasuda Takahiro, Nishiguchi Shuhei, Seki Shuichi
Department of Hepatology, Graduate School of Medicine, Osaka City University, 1-4-3 Asahimachi Abeno-ku, Osaka 545-8585, Japan.
J Med Virol. 2005 Jan;75(1):35-41. doi: 10.1002/jmv.20233.
Acute hepatitis C is known to respond better to interferon therapy than chronic hepatitis C. The reason for this difference remains unclear. The present study was undertaken to examine HCV quasispecies in blood from patients with acute hepatitis C caused by accidental exposure to blood-borne pathogens and in blood from the source patients. Three patients who developed hepatitis C (recipient patients; R-Pt.) and two patients who served as a source of HCV infection (source patients; S-Pt.) were the subjects of this study. The number of quasispecies and the genetic diversity in hypervariable region-1 (HVR-1) were examined on the basis of fluorescence single-strand conformation polymorphism and sequence analysis (FSSA). On the day of the accident, the number of quasispecies and genetic diversity were 13 and 36 in S-Pt.1 and 6 and 20 in S-Pt.3, respectively. At the time of diagnosis of acute hepatitis, the number of quasispecies and nucleotide diversity were 2 and 2 in R-Pt.1, 2 and 0 in R-Pt.2, and 4 and 0 in R-Pt.3, respectively. Immediately before the start of treatment, the number of quasispecies and genetic diversity were 4 and 4 in R-Pt.1, 2 and 0 in R-Pt.2, and 3 and 0 in R-Pt.3., respectively. In three R-Pts, interferon therapy resulted in eradication of HCV. These findings indicate that in the early stage of HCV infection, only a portion of HCV transmitted from S-Pts to R-Pts can proliferate. The low number of quasispecies of HCV appears to be one of the reasons why acute hepatitis responds well to interferon therapy.
已知急性丙型肝炎对干扰素治疗的反应比慢性丙型肝炎更好。这种差异的原因尚不清楚。本研究旨在检测因意外接触血源性病原体而感染丙型肝炎的患者血液以及供血者血液中的丙型肝炎病毒(HCV)准种。本研究的对象为3例感染丙型肝炎的患者(受血者;R-Pt.)和2例作为HCV感染源的患者(供血者;S-Pt.)。基于荧光单链构象多态性和序列分析(FSSA)检测高变区1(HVR-1)中的准种数量和基因多样性。事故发生当天,S-Pt.1的准种数量和基因多样性分别为13和36,S-Pt.3的准种数量和基因多样性分别为6和20。在急性肝炎诊断时,R-Pt.1的准种数量和核苷酸多样性分别为2和2,R-Pt.2的准种数量和核苷酸多样性分别为2和0,R-Pt.3的准种数量和核苷酸多样性分别为4和0。在开始治疗前,R-Pt.1的准种数量和基因多样性分别为4和4,R-Pt.2的准种数量和基因多样性分别为2和0,R-Pt.3的准种数量和基因多样性分别为3和0。在3例受血者中,干扰素治疗使HCV得以清除。这些结果表明,在HCV感染的早期阶段,从供血者传播至受血者的HCV只有一部分能够增殖。HCV准种数量较少似乎是急性肝炎对干扰素治疗反应良好的原因之一。